TARGETING MULTIDRUG RESISTANT BACTERIA WITH RAPID ELIMINATION

Bisphosphocin^® class directly disrupts microbial membranes, leading to fast eradication of bacteria.

Antimicrobial Resistance is a growing global threat with grave consequences for all of humanity as it has emerged against most classes of antibiotic drugs. However, the discovery and launch of advanced antimicrobials has not kept pace with the threat.

Lakewood Amedex has discovered a New Class of Antimicrobial – the Bisphosphocin^® class. In multiple laboratory (in vitro) tests of antimicrobial resistance, Bisphosphocin^® compounds have not shown susceptibility to mechanisms of resistance.

iDFU – A MAJOR COMPLICATION IMPACTING MILLIONS OF DIABETIC PATIENTS WORLDWIDE

Our Lead Compound, Nu-3, for Infected Diabetic Foot Ulcers (iDFU)

iDFU is a major complication affecting millions of diabetic patients worldwide:

• ~830 million patients worldwide suffer from diabetes. Close to 40 million are in the U.S.
• 1/3 will develop a diabetic foot ulcer in their life, of which about 50% will be infected at some point. Many patients experience multiple iDFUs.
• 15% to 20% of iDFU are caused by resistant pathogens, primarily MRSA (Methicillin-resistant Staphylococcus aureus).

Our APPROACH
Bisphosphocin^® compounds rapidly kill bacteria and fungi by depolarizing microbial cell membranes/walls, leading to cell death within minutes—swiftly eliminating the microbes directly at the site of infection

Learn more about topically applied Nu-3 for iDFU and the rest of our pipeline.

ADDRESSING A CRITICAL NEED FOR PATIENTS AND HOSPITAL SYSTEMS

The rapid rise of resistant pathogens has rendered many existing antibiotics ineffective, increasing the risk of severe infections, prolonged hospital stays, amputations, and substantial economic burdens.

Bisphosphocin^® compounds have the potential to save millions of dollars in hospital stays and avoid lengthy treatments typical of conventional standard of care antibiotics.